Fish oil supplements are big business. The worldwide omega-3 market has recently been valued at around $5 billion with 40% growth predicted between 2010 and 2015. Omega-3 fatty acids are fats responsible for many important jobs in the body. We get these fats through our daily diets and the three major omega-3 fats are: Alpha [read the full story…]
Memory clinics are becoming more widespread in the UK and elsewhere. They offer assessment, support, information and advice to people with memory problems and their carers. GPs will often refer patients to memory clinics if they feel that they may be in the early stages of dementia, but need an assessment before a diagnosis can [read the full story…]
The Commissioning for Quality and Innovation (CQUIN) payment framework enables commissioners to reward excellence by linking a proportion of providers’ income to the achievement of local quality improvement goals. The framework aims to embed quality within commissioner-provider discussions and to create a culture of continuous quality improvement, with stretching goals agreed in contracts on an [read the full story…]
People with Alzheimer’s disease experience a loss of nerve cells that use a chemical called acetylcholine as a chemical messenger. Dementia symptoms become more severe as more nerve cells are lost. Cholinesterase inhibitors are a group of drugs (including donepezil, rivastigmine and galantamine) that prevent the enzyme acetylcholinesterase from breaking down acetylcholine in the brain. [read the full story…]
Regular readers may recall previous blogs where I have written about the dangers associated with antipsychotic drugs in elderly patients. Many of you have responded simply and emotionally on Twitter by saying: “Stop prescribing these drugs!” Others have recognised that the issue is far from clear cut as a fair proportion of patients do have [read the full story…]
Mood, memory and behaviour are all affected by dementia and it is not unusual for behaviour to become ‘challenging’. People with dementia may become agitated or aggressive and this can be extremely difficult and stressful for family members and carers. Challenging behaviour has traditionally been managed with antipsychotic drugs, despite the fact that they do [read the full story…]
This topic has been well publicised in recent years and for good reason. We know that there is a huge disparity between the number of people with dementia who are prescribed antipsychotics (180,000 in England each year) and the number who may derive some benefit from the treatment (36,000). We also know that dangerous side [read the full story…]
Alzheimer’s disease affects 1-2% of people aged 65-70 and approximately 20% of those over 80 years. As our population ages, the condition is on the increase and it’s estimated that 2030, an estimated 7.7 million Americans aged 65 and older will have Alzheimer’s disease. We do not yet know exactly how and why Alzheimer’s disease [read the full story…]
The Joint Commissioning Panel for Mental Health (JCP-MH) have published the first of their guides aimed at GPs who will soon be commissioning mental health services. Each of the guides provide a description of what a ‘good’ service configuration should look like, and brings together scientific evidence, service user and carer experience, and case studies [read the full story…]
Our colleagues at the Mental Elf found this small randomised controlled trial looking at the use of memantine for people with Down syndrome and dementia. The trial is being reported in the Lancet. People with Down’s syndrome are more likely to develop dementia than others and one in three will have the illness as early [read the full story…]
